Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024

Rhea-AI Summary

Altimmune, Inc. (ALT) will report its Q4 and full year 2023 financial results on March 27, 2024, with a business update. A conference call will be held at 8:30 am E.T. on the same day. The call will be webcast live on Altimmune's Investor Relations website, with a replay available for three months.

GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024 and will provide a business update.

Altimmune management will host a conference call at 8:30 am E.T. on March 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.

Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.

About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor Contact:
Richard Eisenstadt                                                        
Chief Financial Officer                                                 
Phone: 240-654-1450                                                        
reisenstadt@altimmune.com

Media Contact:
Danielle Cantey
Inizio Evoke Comms
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com

FAQ

When will Altimmune report its Q4 and full year 2023 financial results?

Altimmune will report its Q4 and full year 2023 financial results on March 27, 2024.

What time will the conference call be held on March 27, 2024?

The conference call will be held at 8:30 am E.T. on March 27, 2024.

Where can participants access the live webcast of the conference call?

Participants can access the live webcast of the conference call on Altimmune's Investor Relations website at https://ir.altimmune.com/investors.

How long will the replay of the conference call be available?

The replay of the conference call will be available on the Investor Relations website for up to three months.

How can participants register to join the conference call?

Participants can register to join the conference call and receive the dial-in numbers and unique PIN by visiting the provided link.